Physicians' Academy for Cardiovascular Education

Lipids

Challenges for screening and treatment of FH patients in clinical cardiology

5' education - Feb. 13, 2019 - Kausik Ray, Kees Hovingh

How are the guidelines for progressive CAD guiding us in clinical practice?

5' education - Dec. 13, 2018 - John Kastelein, Ulf Landmesser

Progressive CAD despite low LDL-C, an elusive disease?

5' education - Feb. 13, 2019 - Kausik Ray, Wouter Jukema

What are the key issues and challenges impacting clinical management with novel therapeutics lowering cholesterol?

5' education - Feb. 6, 2019 - Kausik Ray, Gilles Montalescot

Cholesterol guidelines in need of major changes?

5' education - Jan. 25, 2019 - Kausik Ray, François Mach

Are very low LDL-c levels safe?

5' education - Jan. 23, 2019 - John Kastelein, Lluis Masana

LDL-c as target in cardiology: The road towards lower targets

5' education - Jan. 22, 2019 - John Kastelein, Chris Packard

Identifying patients for PCSK9 therapy

10' education - Jan. 16, 2019 - Kees Hovingh, MD - Amsterdam, The Netherlands - Online CME

Guidelines and the role of non-statin therapies for high risk ASCVD patients

10' education - Jan. 7, 2019 - Wouter Jukema, MD - Leiden, The Netherlands - Online CME

Targeting PCSK9 in clinical practice: Guidance & future

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands

Landmark trials with PCSK9 inhibitors

10' education - Dec. 11, 2018 - Ph. Gabriel Steg, MD - Paris, France - Online CME

Lowering Lp(a) potently and safely with antisense technology

3' education - Nov. 20, 2018 - Sotirios Tsimikas, MD

New cholesterol guidelines help identify patients at highest risk who will benefit most from treatment

3' education - Nov. 11, 2018 - Neil Stone, MD - Evanston and Chicago, IL, USA

LDL lowering versus LDL eradication; what makes clinical sense ?

10' education - Aug. 28, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands

Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Jennifer Robinson, MD - Iowa city, Iowa, USA

PCSK9 inhibitors may represent the first therapeutic means to lower Lp(a)

3' education - June 29, 2018 - John Chapman - Paris, France

Laboratory investigation of lipids and lipoproteins

10' education - Aug. 21, 2018 - Prof. David Marais - Cape Town, South Africa

Advancing insights into Lp(a) as a causal factor in CVD

3' education - June 29, 2018 - John Chapman - Paris, France

Dietary lipids in perspective

10' education - July 10, 2018 - Prof. David Marais - Cape Town, South Africa

Greater absolute benefit with PCSK9 inhibition in diabetes patients

3' education - July 3, 2018 - Prof. Kausik Ray, Imperial College London, UK

Estimating CV risk and treatment benefit

10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands - Online CME
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (1/3)

The cardiovascular challenge for primary care in diabetes

10' education - June 14, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME

Familial dysbetalipoproteinemia: Pathofysiology, diagnosis and treatment

10' education - Apr. 11, 2018 - Charlotte Koopal - Utrecht, The Netherlands

The role of lipids in CVD prevention: Lessons learned about statins

10' education - June 6, 2018 - Prof. Kees Hovingh - Amsterdam, The Netherlands - Online CME

Familial hypercholesterolemia: Diagnosis and management

10' education - Apr. 10, 2018 - Prof. Frederick Raal - Johannesburg, South Africa

Emerging approaches to dyslipidemia management beyond LDL-c

3' education - Mar. 9, 2018 - VBWG at ACC 2018, Orlando, FL, USA - Eliot Brinton, Salt Lake City, UT, USA

Statin-associated muscle symptoms: real or nocebo effect?

3' education - Mar. 9, 2018 - VBWG at ACC 2018, Orlando, FL, USA - Prof. Paul Thompson, Hartford, CT, USA

Dyslipidemia in diabetes patients

10' education - Apr. 10, 2018 - Prof. Kausik Ray - Imperial College London, UK
Also as CME accredited e-learning

The CANTOS trial: Implications for the management of patients with residual risk

10' education - Nov. 16, 2017 - Prof. Paul Ridker - Boston, MA, USA - Online CME

Anti-inflammatory therapy in the prevention of cardiovascular disease

10' education - Nov. 16, 2017 - Prof. Peter Libby, USA

Twice yearly administration of PCSK9 siRNA yields persistent LDL-c lowering

News - May 21, 2019

New data of the ORION-3 trial demonstrate that twice a year dosing of the siRNA directed at PCSK9 mRNA inclisiran gives sustained and safe lowering of LDL-C by more than 50 percent for up to 3 years, on top of LDL-c lowering therapies.

Homozygous FH in children is clinically more diverse than clinical diagnostic criteria suggest

Literature - May 20, 2019 - Luirink IK et al., - J Clin Lipidol. 2019

LDL-c levels vary greatly among pediatric patients with genetically defined hoFH, and overlap exists between the LDL-c levels and phenotypes of severe heFH and hoFH.

Estimation of required reduction of Lp(a) for a clinically relevant reduction of CHD risk

Literature - May 13, 2019 - Lamina C et al. - JAMA Cardiol. 2019

A mendelian randomization analysis in population-based cohorts assessed that lowering Lp(a) by 65.7 mg/dL yields a similar CHD event risk reduction as lowering LDL-c by 38.67 mg/dL

Many patients initiating statin therapy show sub-optimal LDL-c lowering, resulting in higher CVD risk

Literature - Apr. 29, 2019 - Akyea RK et al. - Heart 2019

In a primary care patient cohort, >50% of patients initiating statin therapy did not show optimal LDL-c lowering, which significantly increased their risk of future CVD events.

Low LDL-c and TG levels associated with risk of hemorrhagic stroke in women

Literature - Apr. 18, 2019 - Rist PM et al., - Neurology 2019

In a large, prospective cohort of women, those with LDL-c <70 mg/dL and potentially those with LDL-c ≥160 mg/dL and those with low TG, showed a higher risk of hemorrhagic stroke.

Majority of statin-eligible US adults not taking a statin were never offered the therapy

Literature - Apr. 11, 2019 - Bradley CK et al. - J Am Heart Assoc. 2019

The PALM registry reveals that 27% of adults who were eligible for statin therapy, did not use it. In almost 60%, this was because they were never offered a statin. Others discontinued, or declined use

Inhibition of enzyme upstream of statin target also lowers LDL-c levels and CV event risk

Literature - Apr. 8, 2019 - Ference BA et al - N Engl J Med 2019

Mendelian randomization study provides genetic validation for ATP citrate lyase as target (of bempedoic acid) in LDL-c lowering to reduce CV risk, to a similar extent as inhibiting HMGCR with a statin.

Challenges for screening and treatment of FH patients in clinical cardiology

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Feb. 13, 2019 - Kausik Ray, Kees Hovingh
Identification of FH in ACS patients is crucial, as it has an impact on the clinical trajectory. Prof. Hovingh discusses how to classify these patients and their prognosis.

Identification of FH in ACS patients is crucial, as it has an impact on the clinical trajectory. Prof. Hovingh discusses how to classify these patients and their prognosis.

Causal association of LCL-c with ischemic stroke and intracerebral hemorrhage

Literature - Mar. 29, 2019 - Sun L et al. - Nature Medicine 2019
Observational and genetic analyses found a causal positive association of LDL-c with ischemic stroke and a causal negative association with ICH in a Chinese population. Using randomized trial data, a net benefit for the prevention of overall stroke with lowering LDL-c was shown.

Observational and genetic analyses found a causal positive association of LDL-c with ischemic stroke and a causal negative association with ICH in a Chinese population. Using randomized trial data, a net benefit for the prevention of overall stroke with lowering LDL-c was shown.

PCSK9 inhibition: Science, outcomes & guidance

CME accredited E-Learning

Online-CME - This course consists of an introduction and 3 lectures
This course consists of an introduction and 3 lectures

CME accredited course focussed on PCSK9 inhibitors as novel strategy to reduce LDL-C. Member registration (free) is needed to enroll in this course

Large absolute benefit with PCSK9 inhibitor in ACS patients with polyvascular disease

Literature - Mar. 27, 2019 - Jukema JW, et al. - JACC 2019

A prespecified analysis of the ODYSSEY OUTCOMES trial showed a higher incidence of MACE and death in ACS patients with polyvascular disease and alirocumab treatment resulted in a large absolute benefit in these patients.

How are the guidelines for progressive CAD guiding us in clinical practice?

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Dec. 13, 2018 - John Kastelein, Ulf Landmesser
Depending on individual patient characteristics, novel therapeutic approaches can reduce CV risk, particularly in patients at high CV risk. Prof. Landmesser expects that future guidelines will reflect these developments.

Depending on individual patient characteristics, novel therapeutic approaches can reduce CV risk, particularly in patients at high CV risk. Prof. Landmesser expects that future guidelines will reflect these developments.